Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.

@article{Muir2002HeterogeneityOS,
  title={Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.},
  author={Keith Muir},
  journal={Stroke},
  year={2002},
  volume={33 6},
  pages={
          1545-50
        }
}
BACKGROUND AND PURPOSE Tissue substrates for action of neuroprotective agents may be absent in a significant proportion of strokes. Pathophysiological heterogeneity is a possible contributor to negative neuroprotective trials. METHODS Stroke subtypes and their individual outcomes in neuroprotective trial control populations were used to derive models incorporating accuracy of clinical classification and probability of an ischemic penumbra. With the use of treatment effect sizes from… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS, ESTIMATED 52% COVERAGE

87 Citations

0510'02'05'09'13'17
Citations per Year
Semantic Scholar estimates that this publication has 87 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Is there an apparent diffusion coefficient threshold in predicting tissue viability in hyperacute stroke ?

  • S Warach, LC Pettigrew, +6 authors R Gammans
  • Stroke
  • 2001

Similar Papers

Loading similar papers…